1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Endovascular treatment and devices used
Case No. Occlusion Sites Spasmolytic Agents Timing of Drug Therapy Mechanical Device No. of Balloon Inflations 1 L M2 ReoPro Post Merci 3 Maverick, 2 × 9 mm, Neuroform 2 2 L M2/M3 bifurcation ReoPro, Activase Intra, Post Maverick, 1.5 × 9 mm 2 L M2 3 L M3 ReoPro Post Maverick, 2.5 × 15 mm, Wingspan, Enterprise 2 L M2/M3 bifurcation 4 L M3 ReoPro Pre Maverick, 2.0 × 15 mm 4 L M2 L M1 5 L M2 ReoPro Post Merci 2 L M1 Maverick, 1.5 × 20 mm 6 R M3 Alteplase Pre, Intra Maverick, 1.5 × 9 mm 4 R M2 7 R M3 IV rtPA,a ReoPro, nitroglycerin Post Maverick, 1.5 × 15 mm 3
a rtPA given in the ED at 2.5 hours after onset of symptoms; patient received endovascular treatment due to persistence of neurologic symptoms.